ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Bridging the clinical trial gap in Saudi Arabia: a multi-stakeholder conference-based consensus on strategic initiatives for global competitiveness and patient inclusion.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical trial ecosystem of Saudi Arabia has advanced significantly, with innovative industry-sponsored clinical trials (iCTs) growing by 27% from 2018 to 2023, reaching 51.4% in the first half of 2025. However, the Kingdom remains underrepresented in global research. This study aimed to quantify this gap and develop strategies to enhance Saudi Arabia's competitiveness.
methodsA mixed-methods research design was employed. Phase 1 involved a quantitative landscape analysis of historical and current iCT data (2016-2023) using the LongTaal Clinical Trial Informatics platform. Phase 2 involved a qualitative assessment of expert input derived from two national clinical trial conferences (2022 and 2024), in which expert panel discussions and documented outputs were used to contextualize findings and inform strategic recommendations.
resultsIn 2023, Saudi Arabia's iCT market share was < 0.06%, significantly lower than its ~ 0.9% share of global pharmaceutical consumption. This 16-fold disparity highlights a critical lack of patient representation. Economic modelling indicates that achieving parity could increase annual research and development (R&D) investment from ~ USD 46 million to over USD 740 million. Insights derived from conference-based expert discussions highlighted regulatory timelines, infrastructure fragmentation, and insufficient incentives as primary barriers.
conclusionTo bridge this gap, the authors propose operationalizing a centralised national body to serve as a "one-stop shop" for global sponsors. Strategic priorities include harmonizing regulatory timelines to 6 months, establishing distributed Centres of Excellence, and implementing direct R&D financial incentives. These measures are essential to ensuring Saudi patients are adequately represented in the development of novel pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.